Here’s how Tandem Diabetes Care insider buying predicted a move from $2 to $50 in 9 months.


In early 2018 aggressive insider buying in  Tandem Diabetes Care (TNDM) — then trading just above $2 a share – presaged a huge gain for the stock. By September of that year TNDM had surged from a market cap of $25 million to over $2.92 billion.  Back in Jan. of 2018 TNDM was just one of a hundred small cap heath care companies with more potential than profits. Bankruptcy seemed more likely than breakout success. No one suspected a huge price gain? Well, almost no one.

On February 13, 2018, five Tandem Diabetes Care corporate insiders disclosed they purchased $3.87 million of TNDM at $2 per share. The officers and directors bought TNDM shares as part of a $60 million secondary offering. The oversized insider buying by the executives was a prelude to major appreciation. Following the insiders into TNDM would have been amazingly profitable.

Filing Date Insider Title Transaction Buy Date  Shares Avg. Price  Total Holdings Start Holdings End % Change
13-Feb-2018 Allen Dick Director Offering Purchase 09-Feb-2018          60,000  $              2.00  $    120,000 17,058 77,058 352%
13-Feb-2018 Blickenstaff Kim D PRESIDENT & CEO, Director Offering Purchase 09-Feb-2018        750,000  $              2.00  $ 1,500,000 486,490 1,236,490 154%
13-Feb-2018 Twomey Christopher J Director Offering Purchase 09-Feb-2018          75,000  $              2.00  $    150,000 4,308 79,308 1741%
13-Feb-2018 Roeder Douglas A Director Offering Purchase 09-Feb-2018     1,000,000  $              2.00  $ 2,000,000 366,800 1,366,800 273%
13-Feb-2018 Greene Howard E Jr Director Offering Purchase 09-Feb-2018          50,000  $              2.00  $    100,000 11,787 61,787 424%


But hindsight is, as they say, 20-20. Is it possible to use insider buying analysis to identify stocks like TNDM before they skyrocket? What exactly were the “tells” in February of 2018 that suggested TNDM was poised to surge higher?

1. Multi-million-dollar by officers and directors

It makes sense that insiders would buy increasing amounts of stock as the information they possess becomes increasingly valuable. So, if the insiders believe their company’s stock is set to soar, it’s not surprising that insiders might “back up the truck” and buy.  But the Tandem Diabetes Care insider buying was $3.9 million — an especially large buying cluster, especially for a small cap company. It’s obvious insiders believed TNDM shares were a great deal. They could have been wrong, but their conviction was evident in the aggressive purchases.

2. Buying by key executives.

Kim Blickenstaff, TNDM’s President and CEO was a big buyer in the secondary. Director Douglas Roeder, an experienced health care venture capitalist, and a director since 2009, bought $2 million. These two probably knew more about the company than anyone, and they were placing big bets.

3. Tandem Diabetes Care insider buying represented a large % holdings increase by insiders.

CEO Kim Blickenstaff owned 486,490 shares of TNDM before he added 750,000 in the secondary. That’s a 154% increase – sizeable. The other insiders’ position increases were even greater.  These were not token trades – it was smart businesspeople aggressively increasing their skin in the game.

4. Consensus among insiders.

When multiple insiders of a company are buying, the likelihood increases that they are trading based on favorable company information rather than for liquidity or personal reasons. In early February, insiders were consensus buyers, and no TNDM insider had sold a share in over two years.

Interactive Brokers

5. Insider buying at a small cap firm.

When the secondary was announced, TNDM’s market cap was a bit above $25 million. That qualifies as micro-cap. While following insiders of large-cap firms can be profitable, there is more leverage investing in small caps. Mimicking insiders at little companies, while relatively riskier, can lead to huge gains.

6. Insiders buying a big chunk of a secondary.

Secondary offerings are generally perceived as negative by investors – secondaries increase shares outstanding, thus diluting shareholders’ earnings.  Also, offerings are typically priced below market price to entice investors. And Insiders are typically sellers in the offering – not something outside investors like to see. However, though the February TNDM offering was dilutive and priced slightly below market, corporate insiders bought 6.5% of the offering.

7. A great story.

Last, but not least, Tandem Diabetes Care had an intriguing story. The company had developed insulin pumps that were a breakthrough for diabetes sufferers. And with a market cap of $25 million, TNDM was on the verge of challenging Medtronic (MDT) in a market that generated $2 billion+ for MDT in 2017.   This January 11, 2018 article in Seeking Alpha was a table pounder, laying out a bullish case for the stock. If a company has a great story, and insiders are indifferent or are selling, that’s one thing. But if there’s a compelling narrative and insiders are loading up on their own stock, it signals something else – a potentially lucrative opportunity.

Disclaimer: Do not construe anything written in this post or this blog in its entirety as a recommendation, research, or an offer to buy or sell any securities. Everything in this post is meant for educational and entertainment purposes only. I or my affiliates may hold positions in securities mentioned in the article.